By Denny Jacob
Veradigm shares edged up 8.6%, to $13.26, after it affirmed its previously issued guidance for fiscal 2023.
The stock is down 25% on the year.
The healthcare-technology company maintained its forecast of revenue between $615 million and $635 million as well as adjusted earnings per share between 80 cents and 90 cents, which it first issued on March 22.
Veradigm also said that work to conclude its previously disclosed accounting and internal control errors has taken longer than previously expected and that more time is needed to complete its audit procedure. The company said the extended timeline primarily resulted from the need to build a new supplement revenue system tool and extensive manual work to aggregate and map its historical transaction data into the new system tool.
Write to Denny Jacob at [email protected]
Read the full article here